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Abstract
Depression is a leading cause of HIV/AIDS disease burden; it worsens health outcomes and
quality of life. Addressing this problem requires accurate quantification of the extra burden
of depression to HIV/AIDS in a given population, and knowledge of the baseline depression
prevalence in the general population. There has been no previous study of depression in the
general Cameroonian population. The current study attempts to address that important
need. We used the Beck Depression Inventory-II to assess the prevalence and severity of
depressive symptoms in 270 HIV-infected and seronegative Cameroonians. Univariate
analyses showed a trend toward higher depressive symptoms among cases, compared to
controls (p = 0.055), and among older subjects (>40 years), compared to younger subjects
(40 years) (p = 0.059). Analysis of depression severity showed that 33.73% of cases had
moderate-to-severe depressive symptoms, compared to 19.8% of controls (p<0.01). How-
ever, multivariable negative binomial regression analyses showed no effect of age, HIV sta-
tus, CD4 levels, viral loads, ART, or opportunistic infections on the risk of depressive
symptoms. Both univariate and multivariable regression analyses showed significantly
higher risk of depressive symptoms among females compared to males; this was significant
for both female controls and female cases. Female cases had significantly higher CD4 cell
counts and lower viral loads, compared to males. Both univariate and multivariable regres-
sion analyses showed that lower education (10 years) was associated with increased risk
of depressive symptoms. This study shows a high prevalence of depressive symptoms
among seronegative controls and HIV-infected Cameroonians. Integrating care for mental
disorders such as depression into primary health care and existing HIV/AIDS treatment
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programs in Cameroon may improve the wellbeing of the general population and could
lower the HIV/AIDS burden.
Introduction
Depression is a leading cause of disease burden. Recent studies showed that major depressive
disorder is the 2nd leading cause of disability worldwide [1, 2], and is a major cause of suicide
[2–5]. By the year 2030, depression is projected to be one of the three leading causes of illness
worldwide, together with HIV/AIDS and ischemic heart disease [1, 2]. Depression also con-
tributes to the global burden of both non-communicable diseases such as ischemic heart dis-
ease [6], and communicable diseases such as HIV/AIDS [7–14]. Studies in both high- and low-
income countries have reported an association between HIV/AIDS and depression, and dem-
onstrated that depression is associated with worse HIV/AIDS outcomes and poorer quality of
life [7–14].
The Beck Depression Inventory (BDI)-II is one of the most widely used tools in psychomet-
ric research (for review, see [15]). The BDI-II has been translated into many languages, vali-
dated in numerous studies, and shown to reliably measure the symptoms of depression in
populations in both high-income [14–21] and resource-limited countries [7–13, 20, 22–24].
We have used and validated the BDI-II in Cameroon [25]. Previous studies have found high
rates of depressive symptoms among HIV/AIDS patients in Cameroon, with reported preva-
lence of depression ranging from 21 to 63% [26–31]. However, all these studies only examined
HIV-infected subjects and none included seronegative controls. There has been no study of
depression in the general Cameroonian population, and the epidemiology of depression in
Cameroon is not known. In the present study, using the BDI-II, we assessed the prevalence
and severity of depression in HIV-infected and seronegative control individuals in Yaounde´,
Cameroon. We further assessed the influence of age, gender and education on the occurrence
of depression in both groups, as well as the effect of antiretroviral therapy, opportunistic infec-
tions, viral loads, and immune status on the risk of depression in infected individuals.
2. Materials and methods
2.1. Study design and ethical considerations
This cross-sectional study was part of an ongoing research project aimed at analyzing the influ-
ence of HIV genetic diversity on viral neuropathogenesis in Cameroon. The study was per-
formed in accordance with guidelines of the Helsinki Declaration and was approved by the
Cameroon National Ethics Committee, as well as the Institutional Review Board of the Univer-
sity of Nebraska Medical Center. Written informed consent was obtained from all the partici-
pants and data were processed using unique identifiers to ensure participant confidentiality.
2.2. Participants
A total of 270 HIV seropositive individuals and seronegative controls were consecutively
recruited between 2008 and 2015. Cases were recruited from 1) the HIV voluntary counseling
and testing section of the Day-care Service in the Yaounde´ Central Hospital; 2) the Yaounde´
Jamot Hospital; 3) the Efoulan District Hospital, Yaounde´; and 4) the Etoug-Ebe Baptist
Health Center, Yaounde´. Controls were recruited from the same health services, as well as
among 1) caregivers and visitors to the Neurology outpatient clinic and Day-care service in the
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Yaounde´ Central Hospital; and 2) the Health and Social Welfare Centre of the University of
Yaounde´-1. The purpose of the study and research procedures were fully explained to the par-
ticipants, and adults at least 18 years old who gave a written consent were allowed to partici-
pate in the study. The exclusion criteria were: 1) present or past history of CNS disease
unrelated to HIV, 2) head trauma, 3) current alcohol intoxication (blood alcohol content of
each participant was measured using a Breathalyzer), 4) known psychiatric disease or treat-
ment with antipsychotic drugs, and 5) ongoing systemic illness or fever (temperature of
37.5˚C or higher). All subjects enrolled spoke French as their primary language of instruction
and interviews were thus conducted in French.
2.3. Data collection
All participants provided demographic information, underwent a complete medical history, a
general physical examination, and a thorough neurological assessment by neurologists at the
Yaounde´ Central Hospital to detect any focal neurological deficit suggestive of CNS opportu-
nistic infection, before psychometric testing. This thorough clinical assessment of each subject
combined with review of his or her prior medical history and subsequent laboratory data,
ensured that potential confounding factors such as existing CNS opportunistic infections were
ruled out. The Beck Depression Inventory-II [32] was administered to each subject by trained
psychometrists in the Neuropsychology laboratory of the Neurology Department of the
Yaounde´ Central Hospital: a private, quiet and well-lit room. Psychometric testing was done
prior to blood sample collection and laboratory analyses for HIV serology.
HIV serology, CD4 cell counts, and viral loads. Sample collection and all analyses were
performed in the Hematology laboratory of the Yaounde´ University Teaching Hospital, Cam-
eroon. Venous blood samples were collected and stored at room temperature in the outpatient
clinic and analyses performed in the Hematology laboratory within 6 hours of blood collec-
tion. The HIV status of each participant was determined using the rapid immunochromato-
graphic HIV-1/2 test (Abbott Diagnostics, Chicago, IL, USA) and the Murex HIV antigen/
antibody Combination ELISA (Abbott Diagnostics), according to the manufacturer’s instruc-
tions. A participant was considered HIV+ if he/she tested positive for the two tests, HIV- if
negative for both tests, and discordant if positive for only one test. No discordant result was
observed in this study.
Subjects’ CD4 T-lymphocyte counts were quantified by flow cytometry, using a Fluores-
cence Activated Cell Sorting (FACS) Count Instrumentation System and the BD FACSCount
CD4 reagent kit (BD Biosciences, San Jose, CA, USA), according to the manufacturer’s
instructions. The FACS instrument was calibrated and quality control tested before each
experiment. For viral loads quantification, HIV RNA copy number in each plasma sample was
quantified by reverse transcription polymerase chain reaction (RT-PCR), using Amplicor
HIV-1 Monitor Test (Roche Diagnostic Systems, Pleasanton, CA), according to the manufac-
turer’s protocol. The assay detection limit was 50 viral copies / ml.
2.4. Psychometric instruments
2.4.1. Beck depression inventory-II. The Beck Depression Inventory (BDI)-II [15, 32] is
widely used to detect the presence of depressive mood and to measure the severity of depres-
sion. This instrument has been translated into many languages, including French, validated
through back-translations and test-retest reliability. This validated French version of the
BDI-II was shown to accurately diagnose depression in human studies in France [33, 34], Bel-
gium [35], and Canada [36–38]. We previously adapted and validated this French version of
the BDI-II in Cameroon [25], and in our current study, this psychometric test was used to
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detect depression and assess its severity. The BDI-II was administered to each subject by
trained psychometrists in a face-to-face interview. The BDI-II consists of a 21-item question-
naire that assesses affective symptoms of depression, including hopelessness, irritability, feel-
ings of guilt, pessimism, worthlessness, self-dislike, and suicidal thoughts; as well as somatic
symptoms such as loss of appetite, fatigue, difficulties sleeping and concentrating. The answer
to each question was scored on a scaled value of 0 to 3, and the total score determined the
severity of depression: 0–13 indicating minimal depression; 14–19 indicating mild depression;
20–28 indicating moderate depression; 29–63 indicating severe depression [15, 32].
2.4.2. Beck depression inventory fast-screen. The BDI- Fast Screen (FS) is a shorter
7-item instrument that includes questions extracted from the BDI-II [15, 32, 39]. The answer
to each question was scored on a scaled value of 0 to 3, and the FS score determined the sever-
ity of depression: 0–3 indicating minimal depression; 4–8 indicating mild depression; 9–12
indicating moderate depression; 13–21 indicating severe depression [15, 32, 39].
2.5. Statistical analysis
The characteristics of participants were compared between HIV case and control groups using
t-tests or Wilcoxon rank-sum tests for continuous variables, and the Chi-squared or Fisher’s
exact tests for categorical variables. The outcomes of the study, Beck total and Beck FS scores,
were compared between groups using the Wilcoxon rank-sum tests or Kruskal-Wallis tests
because they were not normally distributed. Chi-squared tests, Fisher’s exact tests, or logistic
regressions were used to determine the association between the severity of depression and the
characteristics of participants. Multivariable negative binomial regressions were used to deter-
mine the effects of age, education, HIV status, gender, as well as the interaction between HIV
status and gender on Beck total or Beck FS scores. Multivariable negative binomial regression
analyses were also used to examine the effects of antiretroviral therapy (ART), CD4 levels, and
viral loads on the Beck total or Beck FS scores among HIV-infected patients. Tukey-Kramer’s
correction was used to control for all pairwise comparisons, and Dunnett’s correction was
used for multiple comparisons with a control group [40]. All analyses were performed using
SAS version 9 (SAS Institute, Inc., Cary, NC).
3. Results
3.1. Demographics
A total of 270 (169 HIV+ and 101 HIV-) adult Cameroonians were evaluated. Participants’
demographic characteristics are summarized in Table 1. Amongst the HIV+ subjects, 105
(62.9%) were on ART, whereas 64 (37.1%) were treatment naïve, and 43 (25.6%) had opportu-
nistic infections and were on concurrent antibiotic treatment. Although cases and controls
were recruited from the same health facilities and settings in Yaounde´, there were demo-
graphic differences between the two groups. Compared to cases, controls were significantly
younger: female controls were younger than female cases, and male controls were younger
than male cases (Table 1). Male cases were significantly older than female cases (P<0.01), but
there was no significant difference between the ages of female controls and male controls.
Compared to cases, controls were significantly more educated (Table 1). There was no signifi-
cant difference in education level between female cases and male cases, or between female con-
trols and male controls.
3.2. Clinical and laboratory characteristics of cases
The clinical and laboratory characteristics of the 169 cases are summarized in Tables 2–4. The
overall mean CD4 was 450.36 ± 261 cells/ μl; 464.31 ± 244.34 cells/ μl for females and
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394.58 ± 317.78 cells/ μl for males; 367.8 ± 215 cells/ μl for treatment naïve cases and
503.5 ± 273 cells/ μl for cases on ART; 455.83 ± 242.7 cells/ μl for cases 40 years old and
442.17 ± 288.3 cells/ μl for cases > 40 years old. The overall median CD4 was 418 (range: 5 to
1657) cells/ μl, the median viral load was 50 (range: undetectable ( 50) to 14,964,000)
copies/ml; and the median log viral load was 1.69 (range: 1.69 to 7.17) log copies/ml. The viral
load was the 50 copies/ml detection limit in 67.6% of cases. Compared to male cases, female
cases had significantly higher CD4 cell counts (Table 2, P = 0.04) and significantly lower viral
loads (Table 2, P = 0.02). Compared to treatment naïve cases, subjects on ART had signifi-
cantly higher CD4 cells (Table 3, P = 0.0009) and significantly lower viral loads (Table 3,
P< 0.0001). There was no significant difference between younger and older cases with respect
to CD4 counts or viral loads (Table 4).
3.3. Effects of HIV status on depressive symptoms among
Cameroonians
Univariate analysis showed marginally higher median Beck total scores (P = 0.05) among cases
compared to controls (Table 5). Further multivariable negative binomial regression analyses
Table 1. Demographic characteristics of the HIV+ and HIV- groups.
CASES (n = 169) CONTROLS (n = 101) P-value
Cases on ART (n, %) 105/167 (62.9) -
Cases with OI (n, %) 43/168 (25.6) -
Age (mean ± SD) 38.64 ± 9.11 29.47 ± 8.82 <0.0001
Age > 40 years (n, %) 66 (39.05) 13 (12.87) <0.0001
EDU (mean ± SD) 9.79 ± 3.69 13.62 ± 3.62 <0.0001
EDU 10 years (n, %) 100 (59.17) 24 (23.76) <0.0001
EDU 11 to 13 years (n, %) 43 (25.44) 20 (19.8)
EDU 14 years (n, %) 26 (15.38) 57 (56.44)
Females (n, %) 135 (79.88) 68 (67.33) 0.02
Mean Female age ± SD (n) 37.53 ± 8.82 (135) 29.87 ± 9.18(68) <0.0001
Mean Male age ± SD (n) 43.03 ± 9.03(34) 28.64 ± 8.11(33) <0.0001
Mean Female EDU ± SD (n) 9.49 ± 3.69(135) 13.5 ± 3.6 (68) <0.0001
Mean Male EDU ± SD (n) 10.97 ± 3.48 (34) 13.88 ± 3.71(33) 0.002
Speak French (%) 169 (100) 101 (100) 0.99
F: females, M: male; EDU: education, ART: antiretroviral therapy; SD: standard deviation; n: sample size; OI: opportunistic infections
EDU 10 years corresponds to a maximum middle school (8th grade) level education.
EDU 11 to 13 years corresponds to a high school (9th to 12th grade) level education.
EDU 14 years correspond to college and post-graduate level education.
doi:10.1371/journal.pone.0171956.t001
Table 2. Clinical and laboratory characteristics of HIV-infected subjects: CD4 and viral loads of males and females cases.
Variables Gender N Median Minimum Maximum P-value
CD4 (cells/ μl) F 132 449.5 5 1233 0.04
M 33 295 34 1657
VL (copies/ ml) F 135 50 50 5,389,975 0.02
M 34 50 50 14,964,000
VL (Log copies/ml) F 135 1.69 1.69 6.73 0.02
M 34 1.69 1.69 7.17
doi:10.1371/journal.pone.0171956.t002
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Table 4. Clinical and laboratory characteristics of HIV-infected subjects: CD4 and viral loads of younger and older cases.
Variables Age N Median Minimum Maximum P-value
CD4 (cells/ μl) < = 40 99 421 5 1233 0.54
>40 66 395 70 1657
VL (copies/ml) < = 40 103 50 50 5,246,000 0.29
>40 66 50 50 14,964,000
VL (Log copies/ml) < = 40 103 1.69 1.69 6.71 0.3
>40 66 1.69 1.69 7.17
N: sample size; VL: viral loads; ART: antiretroviral therapy; F: females, M: males
doi:10.1371/journal.pone.0171956.t004
Table 3. Clinical and laboratory characteristics of HIV-infected subjects: CD4 and viral loads of cases on ART and treatment naïve.
Variables ART N Median Minimum Maximum P-value
CD4 (cells/ μl) No 60 319.5 34 894 0.0009
Yes 103 483 5 1657
VL (copies/ml) No 62 7460.5 50 14,964,000 < .0001
Yes 105 50 50 1,380,311
VL (Log copies/ml) No 62 3.25 1.69 7.17 < .0001
Yes 105 1.69 1.69 6.14
doi:10.1371/journal.pone.0171956.t003
Table 5. Univariate analysis of depression risks (BDI-II) among Cameroonian subjects.
Outcome Variables N Median
Score
Range P-value
BECK Total Score Status Case 169 14 0–60 0.055
Control 101 12 0–45
Age (y)  40 191 12 0–60 0.059
> 40 79 16 0–44
EDU (y)  14 83 9 0–42 0.002
 10 124 14.5 0–44
11 to 13 63 14 0–60
Gender F 203 14 0–60 0.02
M 67 10 0–40
BECK FS Score Status Case 168 4 0–18 0.13
Control 101 3 0–13
Age (y)  40 191 3 0–18 0.75
> 40 78 3 0–14
EDU (y)  14 82 2 0–17 0.0004
 10 124 3 0–14
11 to 13 63 5 0–18
Gender F 202 4 0–18 0.04
M 67 3 0–10
EDU: education; y: years; F: females, M: males; cases: human immunodeficiency virus (HIV)+; controls: HIV-; ART: antiretroviral therapy; OI: opportunistic
infections; N: sample size
doi:10.1371/journal.pone.0171956.t005
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showed no significant difference in Beck total scores (Table 6, P = 0.91) or Beck FS scores
(Table 7, P = 0.13) of cases and controls; and showed no interaction between gender and HIV
status for both Beck total scores (Table 6, P = 0.88) and Beck FS scores (Table 7, P = 0.18).
Analysis of depression severity based on Beck total scores showed mild-to-no depression in
66.27% of cases, and 80% of controls, and moderate-to-severe depression in 33.73% of cases
compared to 19.8% among controls (Table 8, P = 0.01). However, the difference in Beck FS
scores between cases and controls was not significant by univariate analysis.
Further univariate analysis of cases showed that CD4 levels and viral loads had no effect on
Beck total scores or Beck FS scores (S1 Table). Multivariable negative binomial regression
analyses of cases confirmed these results and showed no significant difference in Beck total
scores (S2 Table) or Beck FS scores (S3 Table) of cases with lower CD4 cells and cases with
higher CD4 cells. Analysis of depression severity (cases with minimal/mild depression vs.
cases with moderate/severe depression) based on Beck total scores and Beck FS scores showed
no significant effect of CD4 levels or viral loads on depression. Similar results were obtained
Table 6. Negative binomial regression analysis of depression risks (BDI-II) among Cameroonian subjects: Analysis based on BECK Total scores.
Variables Coefficient 95% CI P-value
Age (years) > 40 0.19 -0.02 0.41 0.08
 40 Reference
EDU 14 years § -0.25 -0.52 -0.02 0.07
EDU 11 to 13 years § 0.13 -0.14 0.40 0.46
EDU 10 years § Reference
Status Cases -0.02 -0.42 0.37 0.91
Controls Reference
Gender F 0.28 -0.04 0.60 0.09
M Reference
Gender*Status F cases 0.03 -0.40 0.47 0.88
M controls Reference
F: female; M: male; CI: confidence interval;
§ Dunnett-Hsu’s method used to control for multiple comparisons.
doi:10.1371/journal.pone.0171956.t006
Table 7. Negative binomial regression analysis of depression risks (BDI-II) among Cameroonian subjects: Analysis based on Beck FS scores.
Variables Coefficient 95% CI P-value
Age (years) > 40 0.02 -0.23 0.28 0.85
 40 Reference
EDU 14 years§  14 -0.20 -0.52 0.11 0.26
EDU 11 to 13 years § 10 to 13 0.31 0.01 0.61 0.04
EDU 10 years §  10 Reference
Gender F 0.53 0.14 0.92 0.008
M Reference
Status Cases 0.36 -0.11 0.82 0.13
Controls Reference
Gender*Status F Cases -0.35 -0.87 0.17 0.18
M Controls Reference
F: female; M: male; CI: confidence interval; FS: fast screen;
§ Dunnett-Hsu’s method used to control for multiple comparisons.
doi:10.1371/journal.pone.0171956.t007
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using logistic regression analysis (S4 and S5 Tables), Chi-squared tests (S6 and S7 Tables), and
Wilcoxon-rank sum tests (data not shown).
3.4. Effects of age on depressive symptoms among Cameroonians
Univariate analysis of all subjects (all cases and controls combined) based on age showed a
trend toward higher median Beck total scores among subjects over 40 years old, compared to
younger subjects (P = 0.059, Table 5). Separate univariate analyses of controls and cases
showed no significant difference in Beck total scores and Beck FS scores between older and
younger controls, and no significant difference in Beck total scores or Beck FS scores between
older and younger cases. Quantification of depression severity using Beck total scores or Beck
FS scores also showed no significant differences in the proportion of older and younger cases
or older and younger controls with moderate-to-severe depression (Table 8). However, analy-
sis of controls’ Beck total scores showed that a higher proportion of older controls (38.46%)
had moderate-to-severe depression, compared to younger controls (only 17%). Analyses based
Table 8. Severity of depression among cases and controls.
Status Variables Cases (n = 169) Controls (n = 101) P-value
ALL SUBJECTS BECK Total Score Minimal/Mild, n (%) 112 (66.27) 81 (80.2) 0.01
Moderate/Severe, n (%) 57 (33.73) 20 (19.8)
BECK FS Score Minimal/Mild, n (%) 143 (85.12) 90 (89.11) 0.35
Moderate/Severe, n (%) 25 (14.88) 11 (10.89)
Status Variables NoART (n = 62) ART (n = 105) P-value
CASES BECK Total Score Minimal/Mild, n (%) 37 (59.68) 73 (69.52) 0.19
Moderate/Severe, n (%) 25 (40.32) 32 (30.48)
BECK FS Score Minimal/Mild, n (%) 51 (82.26) 90 (85.71) 0.55
Moderate/Severe, n (%) 11 (17.74) 15 (14.29)
Status Variables F (n = 135) M (n = 34) P-value
CASES BECK Total Score Minimal/Mild, n (%) 88 (65.19) 24 (70.59) 0.55
Moderate/Severe, n (%) 47 (34.81) 10 (29.41)
BECK FS Score Minimal/Mild, n (%) 111 (82.22) 32 (94.12) 0.09
Moderate/Severe, n (%) 24 (17.78) 2 (5.88)
Status Variables Age < = 40 (n = 103) Age >40 (n = 66) P-value
CASES BECK Total Score Minimal/Mild, n (%) 69 (66.99) 43 (65.15) 0.81
Moderate/Severe, n (%) 34 (33.01) 23 (34.85)
BECK FS Score Minimal/Mild, n (%) 87 (84.47) 56 (84.85) 0.95
Moderate/Severe, n (%) 16 (15.53) 10 (15.15)
Status Variables F (n = 68) M (n = 33) P-value
CONTROLS BECK Total Score Minimal/Mild, n (%) 54 (79.41) 27 (81.82) 0.78
Moderate/Severe, n (%) 14 (20.59) 6 (18.18)
BECK FS Score Minimal/Mild, n (%) 59 (86.76) 31 (93.94) 0.5
Moderate/Severe, n (%) 9 (13.24) 2 (6.06)
Status Variables Age < = 40 (n = 103) Age >40 (n = 66) P-value
CONTROLS BECK Total Score Minimal/Mild, n (%) 73 (82.95) 8 (61.54) 0.13
Moderate/Severe, n (%) 15 (17.05) 5 (38.46)
BECK FS Score Minimal/Mild, n (%) 80 (90.91) 10 (76.92) 0.15
Moderate/Severe, n (%) 8 (9.09) 3 (23.08)
N: sample size
doi:10.1371/journal.pone.0171956.t008
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on Beck FS scores also showed that 23% of older controls had moderate-to-severe depression,
compared to only 9% of younger controls, but these differences were not statistically signifi-
cant (Table 8).
Multivariable negative binomial regression analyses showed marginally higher mean log
Beck total scores in subjects over 40 years old, compared to younger subjects, although the dif-
ference did not reach statistical significance (P = 0.08, Table 6). Univariate and multivariable
analyses of Beck FS scores showed no difference between the older and younger groups (Tables
5 and 7). Further multivariable analysis of cases, using negative binomial regression analysis,
showed no significant difference in Beck total scores (S2 Table) or Beck FS scores (S3 Table) of
older and younger cases. Multivariable analysis of depression severity based on Beck total
scores (S4 Table) and Beck FS scores (S5 Table) also showed no effect of age on the severity of
depression among cases.
3.5. Effects of education on depressive symptoms among
Cameroonians
In univariate analysis of all subjects (cases and controls combined), subjects with fewer than 14
years of education had significantly higher median Beck total scores (Table 5, P = 0.002) and
Beck FS scores (Table 5, P = 0.0004), compared to subjects who attended college (14 years of
education). Separate univariate analyses of controls and cases showed that compared to less
educated controls, those with at least 14 years of schooling had significantly lower Beck total
scores (P = 0.04) and lower Beck FS scores (P<0.0005). However, analysis of cases showed no
significant differences in Beck total scores or Beck FS scores, between the small numbers of
cases with high levels of education, as compared to a much larger subgroup with lower levels
of education.
Multivariable negative binomial regression analyses of all subjects showed lower mean log
Beck scores in subjects with at least 14 years of education, compared to less educated subjects
(Table 6, P = 0.07), but no significant difference was observed between subjects with a maxi-
mum 10 years education and those with 11 to 13 years of education (Table 6, P = 0.46). Multi-
variable negative binomial regression analysis of Beck FS scores showed no significant
differences between subjects with14 years of education, compared to less educated subjects,
but showed significant differences between subjects with a maximum 10 years education and
those with 11 to 13 years of education (Table 7, P = 0.04).
Additional multivariable negative binomial regression analysis of cases showed no signifi-
cant difference in Beck total scores (S2 Table) or Beck FS scores (S3 Table) of cases with14
years of education, compared to less educated cases. Multivariable logistic regression analyses
of depression severity (cases with minimal/mild vs. moderate/severe depression) based on
Beck total scores showed no effect of education on the severity of depression among cases (S4
Table). However, analysis of depression severity based on Beck FS scores showed higher scores
in subjects with 11 to 13 years of education compared to those with a maximum 10 years edu-
cation (S5 Table, P = 0.04).
3.6. Effects of gender on depressive symptoms among Cameroonians
Univariate analysis of all subjects (cases and controls combined) showed significantly higher
median Beck total scores (Table 5, P = 0.02) and Beck FS scores (Table 5, P = 0.04) among
female compared to male participants. Separate univariate analyses of controls and cases
showed higher Beck total scores (P = 0.08) and significantly higher Beck FS scores (P = 0.009)
among female controls compared to male controls. Analysis of cases showed mean gender dif-
ferences of the same magnitude (albeit not significant) in Beck total scores. Quantification of
Depression in seronegatine controls and HIV/AIDS patients in Cameroon
PLOS ONE | DOI:10.1371/journal.pone.0171956 February 23, 2017 9 / 17
depression severity using Beck total scores showed no significant differences in the proportion
of males and females with minimal-to-mild, and moderate-to-severe depression. However,
Chi-squared analysis of Beck FS scores showed a somewhat higher proportion of female cases
(17.8%) with moderate-to-severe depression, compared to male cases (5.88%) (Table 8,
P<0.09). Similarly, a higher proportion of female controls (13.24%) had moderate-to-severe
depression, compared to male controls (6%), although the difference was not statistically sig-
nificant (Table 8).
Multivariable negative binomial regression analyses showed that there was no significant
interaction between gender and status for each outcome (Table 6, P = 0.88 and Table 7
P = 0.18). Male controls had lower mean log Beck FS score than female cases (P = 0.03) and
lower mean log Beck FS score than female controls (P = 0.04). Additional multivariable regres-
sion analysis without the interaction term showed significantly higher mean log Beck total
scores (Table 9, P = 0.008) and higher mean log Beck FS scores (Table 9, P = 0.01) among
female compared to male participants.
Further multivariable negative binomial repression analysis of cases showed significantly
higher mean log Beck total scores among female cases, compared to male cases (S2 Table,
P = 0.02), but these difference were not significant for Beck FS scores (S3 Table). Multivariable
logistic regression analysis of depression severity (cases with minimal-to-mild vs. moderate-
to-severe depression) showed increased depression among female cases compared to male
cases (coefficient: 0.77, 95% confidence interval: -0.19 to 1.73), although this difference did not
reach statistical significance (S4 Table). Analysis of depression severity based on Beck FS scores
showed significantly increased depression among female cases compared to male cases (coeffi-
cient: 1.73, 95% confidence interval: 0.10 to 3.36; P = 0.04) (S5 Table).
3.7. Effects of ART use and opportunistic infections on depressive
symptoms among HIV-infected Cameroonians
Univariate analysis of cases showed that ART use or the presence of opportunistic infections
did not significantly change the Beck total or FS scores, compared to ART-naïve or cases with
no opportunistic infections. Quantification of depression severity among cases using Chi-
Squared tests, and both Beck total and FS scores, showed no significant differences in the pro-
portion of treatment-naïve cases and cases on ART with moderate-to-severe depression
(Table 8). Similarly, logistic regression analysis of depression severity, using both Beck total
scores (S4 Table) and FS scores (S5 Table) showed no significant effect of ART use on the risk
of depression among cases. Multivariable negative binomial regression analyses confirmed
univariate analysis results and showed no significant difference in mean log Beck total or FS
scores of cases on ART, treatment-naïve cases, and uninfected controls. Further multivariable
negative binomial regression analyses of cases showed no significant difference in mean log
Beck total or FS scores of cases on ART and treatment-naïve cases (S2 and S3 Tables).
Table 9. Negative binomial regression analysis of depression risks (BDI-II) among Cameroonian subjects: Analysis after withdrawing the interac-
tion term (gender*status).
Outcome Gender Estimate 95% CI P-value
Beck Total scores F 0.30 0.08 0.52 0.008
M Reference
Beck FS scores F 0.33 0.07 0.59 0.01
M Reference
F: female; M: male; CI: confidence interval; FS: fast screen
doi:10.1371/journal.pone.0171956.t009
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Discussion
In this study, we analyzed the prevalence and severity of depressive symptoms in both unin-
fected controls and HIV-infected subjects in Cameroon. Our data show relatively high rates of
depressive symptoms in uninfected control subjects in Cameroon; about 20% of seronegative
controls had moderate-to-severe depression, including older and younger subjects, female
(20.59%) and male (18%) controls. This prevalence is within the range of depression preva-
lence reported in the general population in other African countries, including studies using
different psychometric instruments such as the Center for Epidemiologic Studies Depression
Scale (CES-D) in South Africa that showed 20.5% and 13.5% prevalence of depressive symp-
toms among females and males, respectively [41]. A Ugandan study using the Hopkins Symp-
tom Checklist-25, showed a 29% depression prevalence [42]. The 20% prevalence of depressive
symptoms in our seronegative controls is also in line with findings in other countries using the
BDI-II instrument. A systematic review of 54 studies on depression, including 31 cross-sec-
tional studies involving 9447 individuals, and 23 longitudinal studies involving 8113 individu-
als, showed that the pooled prevalence of depressive symptoms was 28.8% [20]. For the 9
studies in this review that used BDI-II, the sample size varied from 43 to 268 subjects, and four
studies showed a 10 to 25.6% prevalence of mild-to-severe depressive symptoms [43–46] while
five studies showed 30 to 63% prevalence of mild-to-severe depressive symptoms [45, 47–50].
However, none of these 9 studies that used BDI-II was conducted in Africa; only one of the
total 54 studies included in this review was conducted in Africa (Kenya) and only two were
conducted in low-income countries.
Other population studies in SSA and the US reported lower depression prevalence. Studies
of the general population and seronegative adults in Nigeria [13, 51], Ghana [52], and South
Africa [52–54] using the Composite International Diagnostic Interview (CIDI) or BDI-II [13]
showed 2.7% to 12% depression rates. Studies of US adult population, including African
American [55], using the PHQ-9 [56] or BDI-II [55, 57], showed 6% to 11% prevalence of
moderate-to-severe depression. These prevalence estimates are lower than the 20% rate in our
controls, and depression rates reported in other studies [41, 42, 45, 47–50]. It is possible that
the different psychometric instruments used in these studies may account for some of the dif-
ferences. It is also possible that the standard cut-off scores of these psychometric instruments,
most of which were standardized and established based on the US population, may not be opti-
mal when applied to populations in other countries.
Factors such as unemployment and poverty have been associated with increased risk of
depressed mood [58–62]. Cameroon has a 33.6% unemployment rate, 75% underemployment
rate, and 44.6% of Cameroon’s 22.8 million inhabitants live near poverty or in poverty [63].
These factors, combined with other societal factors associated with poverty and hardship,
could help explain the high prevalence of depressive symptoms in apparently healthy individu-
als in our study. This shows that depression may be a serious health issue in the general Cam-
eroon population, and treatment and care for depression and other mental disorders should
be included in the country’s health care system.
In the current study, univariate analyses of Beck total and FS scores showed significantly
higher prevalence of depressive symptoms among HIV-infected subjects in Cameroon, with
33.73% having moderate-to-severe depression, compared to 20% of controls. Previous stud-
ies using different psychometric instruments also showed the presence of depressive symp-
toms among HIV-infected subjects in Cameroon. Studies using the PHQ-9 [26, 27] or CIDI
[28], with a sample size of 100 to 400 subjects, reported a 63% [26], 28.7% [27], and 21% [28]
prevalence of moderate-to-severe depression among HIV-infected subjects. Our findings of
a 33.7% prevalence of moderate-to-severe depression among HIV-infected subjects agree
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with these previous findings and confirm that depression is a serious health issue among
HIV-infected, as well as uninfected individuals in Cameroon. Furthermore, our results are in
agreement with studies reported elsewhere using the BDI-II. Studies of HIV/AIDS patients
in Brazil showed moderate-to-severe depression in 27.6 to 36% of patients, and showed that
the presence of depressive symptoms was associated with lower quality of life [7–9]. A study
of HIV-infected subjects in Korea [14] and France [62] showed moderate-to-severe depres-
sive symptoms in 19.7 to 21% of the subjects. Studies in other SSA countries using BDI-II
also showed increased prevalence of moderate-to-severe depressive symptoms among HIV-
infected subjects, including in 18.9% of HIV-infected adolescents in Malawi [10], in 37.6 to
40% of infected subjects in South Africa [11, 12] and in 29 to 32% of HIV/AIDS patients in
Nigeria [13].
Although univariate analyses showed higher Beck total scores among cases compared to
controls in our current study, there was no significant difference in Beck FS scores, and multi-
variable analysis controlling for other co-factors such as age, education, and gender showed no
significant difference in Beck total or FS scores of cases and controls. This suggests that these
cofactors may have significant effects on the differential results observed. Further analyses
showed that age did not significantly influence the risk of depressive symptoms either among
cases or among controls, but education did. Both univariate and multivariable analyses showed
that for the control group, having a lower education level was associated with increased risk of
depressive symptoms, compared to those with college or postgraduate education. Although
education did not significantly impact the prevalence of depressive symptoms among cases,
analysis of Beck FS scores showed impact of education on depression severity. Our data con-
firmed previous findings in other countries that lower education level is associated with
increased risk of depression. Studies in Brazil [9, 24], Ghana [61], and France [62] showed that
depressive symptoms among HIV-infected subjects were associated with lower education, low
income, unemployment and lower quality of life. However, we did not have information on
the employment status and income levels of our study population, and could not assess their
impact on the risk of depression.
Studies in both high-income and resource-limited countries have shown that depression is
more common among women than men [13, 16, 64–67] and WHO estimates that the burden
of depression among women is 50% higher than in men [68, 69]. In the current study both
univariate and multivariable analyses showed significantly higher prevalence of depressive
symptoms among females, compared to males, and subgroup multivariable analyses showed
gender differences of the same magnitude. Analysis of depression severity also indicated that
the percentage of female cases with moderate-to-severe depression was triple that of male
cases, and the percentage of female controls with moderate-to-severe depression was double
that of male controls. These data confirmed reports from other countries regarding gender dif-
ferences in rates and severity of depressive symptoms. Our study showed that CD4 levels, viral
loads, ART use, or opportunistic infections were not associated to the likelihood of having
depression among cases. This agrees with previous studies of HIV/AIDS patients in both
urban [26] and rural [27] areas in Cameroon that showed, using PHQ-9, a lack of correlation
between ART use and depression.
In summary, our current study shows high rates of depressive symptoms consistent with
moderate-to-severe depression in both seronegative controls (20%) and HIV-infected (33.7%)
Cameroonians, suggesting that it is not only necessary to integrate care for mental disorders
such as depression into existing HIV/AIDS care programs in Cameroon, but also into the gen-
eral primary care system, as this would likely reduce the morbidity and mortality from other
diseases in the country.
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Study Limitations
Like most psychometric tests currently used to detect and characterize depression, the BDI-II is
a self-report inventory, and scores can be influenced by subjective biases in filling out the forms,
as well as by the way questionnaires are administered, and by whom [39]. To minimize these
limitations, all questionnaires were administered to each subject by trained psychometrists in
the Neuropsychology laboratory, a private, quiet and well-lit room in the Neurology Department
of Yaounde´ Central Hospital. For each subject, the same psychometrists who conducted the
interview also scored each form, and our findings are within the range of depression prevalence
reported among the general population [20, 41–50] and HIV-infected subjects [7–9, 11–13] in
other studies. Another limitation of this study is the fact that compared to cases, controls were
much younger, more educated, and had a higher proportion of male participants. We attempted
to address this limitation by performing separate within group analyses, looking at within-group
effects of age, education, and gender on BDI-II scores. Additional limitations include the
absence of employment and income status of study participants; factors such as unemployment,
low income and poverty are associated with increased stress and higher risk of depression [13,
58–62, 67]. This study was conducted in Yaounde´, a large urban area, using a convenience sam-
ple of individuals whose characteristics might not be representative of Cameroon’s general pop-
ulation. Follow-up studies with larger sample size using subjects from other areas of Cameroon,
including semi-urban and rural areas, will be required to generalize the findings, and to better
understand the burden and determinants of depressive disorders in Cameroon.
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